1.7 Gout Pharmacology

0.0(0)
studied byStudied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/111

flashcard set

Earn XP

Description and Tags

Briski :((((((

Last updated 1:21 AM on 2/13/26
Name
Mastery
Learn
Test
Matching
Spaced
Call with Kai

No analytics yet

Send a link to your students to track their progress

112 Terms

1
New cards

gout is a form of ____ charcterized by recurrent episodes of joint pain and inflammation

arthritis

2
New cards

gout joint pain and inflammation is caused by…

MSU crystal deposits in joint and soft tissues

3
New cards

MSU crystals form as a result of …

elevated urate concentrations

4
New cards

MSU crystal localization in the urinary tract can lead to…

kidney stones and urinary obstruction

5
New cards

hallmark of gout

tophi

6
New cards

what is tophi

hard nodules of MSU crystals present in peripheral joints

7
New cards

tophi initially start in…

a single joint (usually big toe)

8
New cards

T or F:

hyperuricemia is always the cause of gout

F

9
New cards

uric acid metabolism:

uric acid is the end product of ____ metabolism

purine

10
New cards

what three things can increase serum uric acid concentration

increased uric acid production

reduction in uric acid renal excretion

combination of both

11
New cards

overproduction of serum uric acid accounts for ____ gout cases

10%

12
New cards

overproduction of uric acid can result from…

excessive de novo purine synthesis

excess dietary intake

myeloproliferative derivates

13
New cards

what is a nucleoside

nitrogenous base and sugar

14
New cards

what is a nucleotide

nitrogenous base, sugar, and phosphate groups

15
New cards

purine levels are controlled by…

de novo synthesis and salvage pathways

16
New cards

the first step in de novo syntehsis of purine is…

PRPP + glutamine via amidoPRT

17
New cards

which enzyme is responsible for the first step in the de novo pathway of making purines

amido pRT

18
New cards

amidoPRT is _____ activated by levels of PRPP

allosterically

19
New cards

when PRPP is high, amidoPRT activity is

high

20
New cards

in the salvage pathway ___ transforms dietary adenine and guanine to ATP and GTP for use in nucleic acid synthesis

HGPRT

21
New cards

In the salvage pathway, HGPRT transforms dietary ______ to the nucleotides ATP and GTP, respectively, for use in nucleic acid synthesis.

adenine and guanine

22
New cards

In the salvage pathway, HGPRT transforms dietary adenine and guanine to the nucleotides ____ and ____, respectively, for use in nucleic acid synthesis.

ATP and GTP

23
New cards

purines adenine and guanine are converted to _____

hypoxanthine

24
New cards

hypoxanthine is transformed to ____

xanthine

25
New cards

xanthine is converted to _____ by xanthine oxidase

uric acid

26
New cards

what enzyme is responsible for converting hypoxanthine to xanthine and then xanthine to uric acid?

xanthine oxidase

27
New cards

xanthine oxidase function

conversion of hypoxanthine to xanthine and then xanthine to uric acid

28
New cards

what drug can reduce urate synthesis by blocking xanthine oxidase?

allopurinol

29
New cards

what drug can increase urate excretion

probenecid

30
New cards

what drug can increase the conversion of urate to allantoin

uricase

31
New cards

synovial joint:

the fibrous capsule is continuous with _______

periosteum of adjacent bone

32
New cards

synovial joint:

the _____ is continuous with periosteum of adjacent bones

fibrous capsule

33
New cards

synovial joint:

the synovial membrane lines _____ of the joint

nonarticular surfaces

34
New cards

any variable that decreases the solubility of urate can promote…

urate crystal deposition

35
New cards

urate is LESS soluble at ___ temps

lower

36
New cards

urate is less soluble at lower temps which explains why urate crystals are…

peripherally distrubuted

37
New cards

synovial joint fluid is more ___ than blood which favors crystal formation

acidic

38
New cards

in an acute attack of gout, MSU binds to _____ which activates them

monocyte toll like receptors

39
New cards

in acute attack of gout:
1. MSU binds to monocyte toll like receptors which activates them

  1. which leads to…

phagocytosis of MSU crystals w intracellular assembly of inflammatory response enzymes

40
New cards

lowkey slide 9 ????

idk girl

41
New cards

Asymptomatic hyperuricemia plasma urate levels

>6.0 mg/dL in women >7.0 mg/dL in men

42
New cards

Asymptomatic hyperuricemia pharmacological intervention

none

43
New cards

Acute gout features

Acute arthritis, typically 1st metatarsophalangeal joint (big toe), excruciating pain

44
New cards

acute gout pharmacological intervention

NSAIDS, colchicine, glucocorticoids

45
New cards

Intercritical phase features

Asymptomatic hyperuricemia

46
New cards

Intercritical phase pharmacological intervention

none

47
New cards

Chronic gout features

Hyperuricemia, development of tophi, Recurring attacks of acute gout

48
New cards

Chronic gout pharmacological intervention

Allopurinol, probenecid, sulfinpyrazone

49
New cards

Non selective NSAIDs ADE:
GI

GI bleeding or ulceration

50
New cards

nonselective NSAIDs ADE:

platelets

inhibition of platelet aggregation

51
New cards

which non selective NSAID is the least likely to cause GI upset?

ibuprofen

52
New cards

which non selective NSAID is the most likely to cause GI upset?

piroxicam

53
New cards

COX2 inhibitor NSAIDs:

effect on platelets

do not effect platelets at normal doses

54
New cards

which is better for pts with risk of GI bleed or taking chronic anticoagulants with gout?

a. nonselective NSAIDs

b. COX 2 NSAIDs

b

55
New cards

potential adverse CV effects of NSAIDS

aggravation of hypertension, causation of renal failure, inhibition of diuretic-induced increases in renal sodium excretion, and reduction of hypotensive effect of diuretics and other anti-hypertensive drugs.

56
New cards

Colchicine MOA

Inhibition of microtubule polymerization, diminished action of chemokine inflammatory mediators, decreased neutrophil activation.

57
New cards

Colchicine ADE

Diarrhea, nausea, vomiting; myelosuppressive

58
New cards

in the presence of cyanocobalamin, colchicine may…

decrease cyanocobalamin concentrations

59
New cards

in the presence of HMG-CoA reductase inhibitors, colchicine may…

may increase rhabdomyolysis drug effects

60
New cards

in the presence of P-gp/ABCBI inducers, colchicine may…

decrease P-pg substrate levels

61
New cards

in the presence of _______, colchicine may decrease cyanocobalamin concentrations

Cyanocobalamin

62
New cards

in the presence of _______, colchicine may increase rhabdomyolysis drug effect

HMG-CoA reductase inhibitors

63
New cards

in the presence of ________, colchicine may decrease P-pg substrate levels

P-gp/ABCBI inducers

64
New cards

serum colchicine levels may be increased by…

CYP3A4 inhibitors; Digoxin; Fosamprenavir; Grapefruit juice; P-pg/ABCBI inhibitors; Tacrolimus; Tipranavir

65
New cards

in the presence of colchicine: Conivaptan, Mifepristone, Stiripentol may…

increase serum CYP3A4 substrate levels

66
New cards

in the presence of colchicine _____ may increase serum CYP3A4 substrate levels

Conivaptan, Mifepristone, Stiripentol

67
New cards

in the presence of colchicine, _______ may increase colchicine myopathic effects

Fibric acid derivatives

68
New cards

in the presence of colchicine, Fibric acid derivatives may…

increase colchicine myopathic effects

69
New cards

glucocorticoid ADE

osteoporosis; myopathy, peptic ulcer disease, CNS effects, hypertension, predisposition to infections; possible glucose intolerance.

70
New cards

glucocorticoid ADE are minimal with ____ treatments for acute gout attacks

short term

71
New cards

____ are highly effective, rapid-acting anti-inflammatory agents with a favorable risk vs. benefit profile.

glucocorticoids

72
New cards

non-pharma interventions for gout

ice, reduce alcohol use, minor dietary modifications, decreased body weight

73
New cards

allopurinol is a structural analog of _____

xanthine

74
New cards

allopurinol MOA

inhibition of uric acid production

75
New cards

allopurinol is oxidized by XO to produce _____

oxypurinol

76
New cards

oxypurinol inhibits XO by….

preventing molybdenum in the enzyme active site from converting between +4 and +6 oxidation states, thereby ‘freezing’ the enzyme

77
New cards

allopurinol is assoc with which rare and life threatening reaction?

allopurinol hypersensitivity syndrome

78
New cards

symptoms of allopurinol hypersensitivity syndrome

erythematous rash, fever, hepatitis, eosinophilia, leukocytosis, renal failure; usually begin within 8 weeks of therapy

79
New cards

risk factors of allopurinol hypersensitivity syndrome

HLA-B*5801 genotype; renal impairment; concomitant diuretic use; female sex; age

80
New cards

drug interactions:

allopurinol and ampicillin or amoxicillin

Increase Co-administration increases rate of skin rxn

81
New cards

drug interactions:

allopurinol and azathioprine

Increase in azathioiprine metabolite production

82
New cards

drug interactions:

Allopurinol and carbamazepine

Increase serum concentrations

83
New cards

drug interactions:

allopurinol and pegloticase

Adverse toxicity is enhanced, increasing risk of anaphylaxis and infusion rxns

84
New cards

drug drug interactions:

allopurinol and theophylline

Increased plasma levels and possible toxicity

85
New cards

drug drug interactions:

allopurinol and warfarin

Enhanced anti-coagulation effect

86
New cards

drug drug interactions:

allopurinol and ACE inhibitors

Elevated risk of hypersensitivity rxn to allopurinol

87
New cards

drug drug interactions:

allopurinol and loop diuretics

increased serum concentrations and incidence of hypersensitivity rxns to allopurinol

88
New cards

Febuxostat is a non-purine xanthine oxidase inhibitor and is ___ selective than allopurinol

more

89
New cards

Febuxostat does not inhibit…

other enzymes involved in purine/pyrimidine metabolism

90
New cards

Febuxostat ADE ADE

increased liver function, N/D, rash, arthralgias

91
New cards

drug drug interactions:

Febuxostat and didanosine

Increased systemic exposure

92
New cards

drug drug interactions:

Febuxostat and Pegloticase

Increased adverse effects with augmented risk of anaphylaxis and infusion rxns

93
New cards

drug drug interactions:

Febuxostat and XO substrate drugs, Mercaptopurine or, theophylline

Increased plasma concentrations, leading to azathioprine toxicity

94
New cards

uricouric agents MOA

block renal tubular uric acid resorption

95
New cards

probenecid MAIN target

URAT1

96
New cards

probenecid can target…

URAT1 and OATs

97
New cards

probenecid increases renal urate excretion and can predispose….

urate stone formation (kidney stone)

98
New cards

probenecid increases ____

renal urate excretion

99
New cards

probenecid can be antagonized by…

low dose aspirin

100
New cards

Sulfinpyrazone has a similar MOA to…

probenecid